A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Clinical trial NCT06062420 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06062420
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-14
- Primary completion
- 2026-09-01
- Enrollment
- 316
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.